Actavis is one of the world’s leading players in the development, manufacture and sale of first class generic pharmaceuticals.

Actavis UK is one of the top 10 UK pharmaceutical companies with a portfolio of products spanning prescription medicine and consumer healthcare brands. It is the second largest provider of generic pharmaceuticals to the NHS.

Actavis has one of the largest pharmaceutical manufacturing sites in the UK. Based in Barnstaple in North Devon the manufacturing site currently produces

1 in 10 prescription medicines dispensed in the UK with an annual capacity to produce approximately 6 billion tablets, capsules and suppositories. Approximately 85% of the volume produced is sold in the UK with the remaining 15% exported to over 85 countries across Europe, Scandinavia, the Middle East and the rest of the globe.

The extensive consumer health range, with over 194 products, includes key brands such as Clamelle, Cymex and Sominex, and innovations such as POM to P switching.

The prescription medicine portfolio has over 540 products available across generic medicine prescription brands and hospital products. This extensive portfolio of products provides the prescriber with a wide range of generic medicines across a number of key therapy areas including:-

- Oncology
- Diabetes
- Analgesics
- Antinfectives
- Central Nervous System
- Cardiovascular

Actavis has an industry leading development pipeline of over 350 products and in the last 3 years have launched over 160 prescription medicines in the UK. In particular, Actavis has developed specific expertise in the launch of “off patent” medicines on the first day of patent expiry. In the last year Actavis successfully launched over 10 products on the first day of patent expiry of the originator branded medicine.

Generic medicines make a significant contribution to the UK healthcare system. Currently around 85% of all medicines dispensed in the UK are prescribed generically saving an estimated £8.6bn for the NHS per annum.